KYTX vs. CABA, EXAI, VALN, ALEC, ADPT, TCRX, LXEO, EDIT, ALLO, and VYGR
Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Cabaletta Bio (CABA), Exscientia (EXAI), Valneva (VALN), Alector (ALEC), Adaptive Biotechnologies (ADPT), TScan Therapeutics (TCRX), Lexeo Therapeutics (LXEO), Editas Medicine (EDIT), Allogene Therapeutics (ALLO), and Voyager Therapeutics (VYGR). These companies are all part of the "biological products, except diagnostic" industry.
Kyverna Therapeutics (NASDAQ:KYTX) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.
Cabaletta Bio received 72 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Kyverna Therapeutics an outperform vote while only 70.00% of users gave Cabaletta Bio an outperform vote.
Kyverna Therapeutics presently has a consensus price target of $42.75, suggesting a potential upside of 223.13%. Cabaletta Bio has a consensus price target of $34.33, suggesting a potential upside of 221.77%. Given Kyverna Therapeutics' higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Cabaletta Bio.
18.1% of Kyverna Therapeutics shares are owned by institutional investors. 9.9% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Kyverna Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity.
Kyverna Therapeutics has higher revenue and earnings than Cabaletta Bio.
In the previous week, Cabaletta Bio had 5 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 9 mentions for Cabaletta Bio and 4 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.69 beat Cabaletta Bio's score of 0.03 indicating that Kyverna Therapeutics is being referred to more favorably in the media.
Summary
Kyverna Therapeutics beats Cabaletta Bio on 8 of the 12 factors compared between the two stocks.
Get Kyverna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kyverna Therapeutics Competitors List
Related Companies and Tools
